Header Logo

Connection

Tammy Meyers to Male

This is a "connection" page, showing publications Tammy Meyers has written about Male.
Connection Strength

0,797
  1. Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis. AIDS. 2019 11 15; 33(14):2197-2203.
    View in: PubMed
    Score: 0,076
  2. Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa. Pediatr Infect Dis J. 2015 Feb; 34(2):175-9.
    View in: PubMed
    Score: 0,055
  3. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa. AIDS. 2013 Mar 13; 27(5):781-5.
    View in: PubMed
    Score: 0,048
  4. Positive association between dietary iron intake and iron status in HIV-infected children in Johannesburg, South Africa. Nutr Res. 2013 Jan; 33(1):50-8.
    View in: PubMed
    Score: 0,047
  5. Changes in pediatric HIV-related hospital admissions and mortality in Soweto, South Africa, 1996-2011: light at the end of the tunnel? J Acquir Immune Defic Syndr. 2012 Aug 15; 60(5):503-10.
    View in: PubMed
    Score: 0,046
  6. Neurodevelopmental delay among HIV-infected preschool children receiving antiretroviral therapy and healthy preschool children in Soweto, South Africa. Psychol Health Med. 2012; 17(5):599-610.
    View in: PubMed
    Score: 0,045
  7. Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa. Pediatr Infect Dis J. 2011 Nov; 30(11):974-9.
    View in: PubMed
    Score: 0,044
  8. Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS One. 2011 Feb 23; 6(2):e17273.
    View in: PubMed
    Score: 0,042
  9. Case records of the Massachusetts General Hospital. Case 18-2010. A 7-year-old boy with elevated HIV RNA levels despite antiretroviral medications. N Engl J Med. 2010 Jun 17; 362(24):2305-12.
    View in: PubMed
    Score: 0,040
  10. Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. AIDS. 2010 Jun 01; 24(9):1341-9.
    View in: PubMed
    Score: 0,040
  11. Six-month gain in weight, height, and CD4 predict subsequent antiretroviral treatment responses in HIV-infected South African children. AIDS. 2010 Jan 02; 24(1):139-46.
    View in: PubMed
    Score: 0,039
  12. HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort. Int J Tuberc Lung Dis. 2009 Jul; 13(7):862-7.
    View in: PubMed
    Score: 0,037
  13. Age-specific and sex-specific weight gain norms to monitor antiretroviral therapy in children in low-income and middle-income countries. AIDS. 2015 Jan 02; 29(1):101-9.
    View in: PubMed
    Score: 0,014
  14. Microbiological investigation for tuberculosis among HIV-infected children in Soweto, South Africa. Int J Tuberc Lung Dis. 2014 Jun; 18(6):676-81.
    View in: PubMed
    Score: 0,013
  15. Effect of baseline immune suppression on growth recovery in HIV positive South African children receiving antiretroviral treatment. J Acquir Immune Defic Syndr. 2012 Oct 01; 61(2):235-42.
    View in: PubMed
    Score: 0,012
  16. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. J Acquir Immune Defic Syndr. 2012 Aug 01; 60(4):369-76.
    View in: PubMed
    Score: 0,012
  17. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012 Jul; 12(7):521-30.
    View in: PubMed
    Score: 0,011
  18. Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children. Eur J Clin Pharmacol. 2012 Apr; 68(4):339-47.
    View in: PubMed
    Score: 0,011
  19. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS. 2011 Jul 31; 25(12):1461-9.
    View in: PubMed
    Score: 0,011
  20. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011 Sep; 27(9):945-56.
    View in: PubMed
    Score: 0,010
  21. Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. Clin Infect Dis. 2011 Feb 15; 52(4):514-21.
    View in: PubMed
    Score: 0,010
  22. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. Antivir Ther. 2011; 16(3):417-21.
    View in: PubMed
    Score: 0,010
  23. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010 Oct 14; 363(16):1510-20.
    View in: PubMed
    Score: 0,010
  24. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA. 2010 Sep 08; 304(10):1082-90.
    View in: PubMed
    Score: 0,010
  25. Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children. AIDS Res Hum Retroviruses. 2010 Jun; 26(6):613-9.
    View in: PubMed
    Score: 0,010
  26. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis. 2010 Apr 15; 201(8):1121-31.
    View in: PubMed
    Score: 0,010
  27. Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS. 2009 Jun 01; 23(9):1097-107.
    View in: PubMed
    Score: 0,009
  28. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2009 Apr 15; 50(5):439-43.
    View in: PubMed
    Score: 0,009
  29. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2008 Apr 15; 47(5):566-9.
    View in: PubMed
    Score: 0,009
  30. The utility of fine needle aspiration in HIV positive children. Cytopathology. 2008 Apr; 19(2):86-93.
    View in: PubMed
    Score: 0,008
  31. High prevalence of subtherapeutic plasma concentrations of efavirenz in children. J Acquir Immune Defic Syndr. 2007 Jun 01; 45(2):133-6.
    View in: PubMed
    Score: 0,008
  32. Surgeons are failing to recognize children with HIV infection. J Pediatr Surg. 2007 Feb; 42(2):431-4.
    View in: PubMed
    Score: 0,008
  33. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med. 2006 Jul; 3(7):e255.
    View in: PubMed
    Score: 0,008
  34. Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res Hum Retroviruses. 2006 May; 22(5):458-65.
    View in: PubMed
    Score: 0,007
  35. Barriers to disclosure to children with HIV. J Trop Pediatr. 2005 Oct; 51(5):285-7.
    View in: PubMed
    Score: 0,007
  36. Full-length genome characterization of HIV type 1 subtype C isolates from two slow-progressing perinatally infected siblings in South Africa. AIDS Res Hum Retroviruses. 2003 Nov; 19(11):1033-7.
    View in: PubMed
    Score: 0,006
  37. Human immunodeficiency virus type 1 envelope-stimulated interleukin-2 production and survival of infected children with severe and mild clinical disease. J Infect Dis. 2001 Sep 15; 184(6):691-8.
    View in: PubMed
    Score: 0,005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.